<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="3004"><DrugName>ebastine</DrugName><DrugNamesKey><Name id="42765133">Bactil</Name><Name id="42754501">Bastel</Name><Name id="42754502">Ebastel</Name><Name id="42952878">Ebastel Flas</Name><Name id="42952880">Ebastel Forte</Name><Name id="42952881">Ebastel Forte Flas</Name><Name id="42765135">Evastel</Name><Name id="42997319">Kestin</Name><Name id="42962691">Kestine</Name><Name id="42997322">Kestinlyo</Name><Name id="42754503">ebastine</Name><Name id="43150272">xarope</Name></DrugNamesKey><DrugSynonyms><Name><Value>Bastel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ebastel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ebastine</Value><Types><Type>USAN</Type><Type>BANN</Type></Types></Name><Name><Value>LAS-W-090</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>W-090</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Bactil</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>LAS-90</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Evastel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>LAS-90DS</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ebastel Flas</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ebastel Forte</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ebastel Forte Flas</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kestine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kestin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kestinlyo</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>xarope</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>90729-43-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14061">Almirall Prodesfarma SA</CompanyOriginator><CompaniesPrimary><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Company id="20073">Pharmacare Ltd</Company><Company id="1019881">Laboratorios Elmor SA</Company><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Company id="1042566">Eurofarma</Company><Company id="1042567">Highnoon Laboratories Ltd</Company><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Company id="16587">Grunenthal GmbH</Company><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Company id="1036448">Novis Pharmaceuticals Llc</Company><Company id="14987">Boryung Pharm Co Ltd</Company><Company id="DOL1000087">Orient Europharma</Company><Company id="1003983">Bayer HealthCare AG</Company><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="21266">Ranbaxy Laboratories Ltd</Company><Company id="1042568">Laboratorios Servimedic</Company><Company id="14061">Almirall Prodesfarma SA</Company><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesPrimary><CompaniesSecondary><Company id="1009547">Sanofi SA</Company><Company id="15872">Eisai Co Ltd</Company><Company id="16832">Nycomed AS</Company><Company id="18101">Merck KGaA</Company><Company id="18105">E Merck India Ltd</Company><Company id="19234">Rhone-Poulenc SA</Company><Company id="27254">Aventis SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3004" type="Drug"><TargetEntity id="135187" type="siDrug">Ebastine</TargetEntity></SourceEntity><SourceEntity id="1002503" type="Company"><TargetEntity id="4297904097" type="organizationId">Takeda Pharmaceuticals International AG</TargetEntity></SourceEntity><SourceEntity id="1003983" type="Company"><TargetEntity id="4297658047" type="organizationId">Bayer HealthCare AG</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="1019881" type="Company"><TargetEntity id="4295922615" type="organizationId">Laboratorios Elmor SA</TargetEntity></SourceEntity><SourceEntity id="1036448" type="Company"><TargetEntity id="4298128595" type="organizationId">Proven Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1038320" type="Company"><TargetEntity id="5035525360" type="organizationId">EIP Eczacibasi Ilac Pazarlama AS</TargetEntity></SourceEntity><SourceEntity id="1042566" type="Company"><TargetEntity id="4296633925" type="organizationId">Eurofarma Laboratorios SA</TargetEntity></SourceEntity><SourceEntity id="1042567" type="Company"><TargetEntity id="4296319527" type="organizationId">Highnoon Laboratories Ltd</TargetEntity></SourceEntity><SourceEntity id="1042568" type="Company"><TargetEntity id="5035525949" type="organizationId">Servimedic SA</TargetEntity></SourceEntity><SourceEntity id="14061" type="Company"><TargetEntity id="4295889280" type="organizationId">Almirall SA</TargetEntity></SourceEntity><SourceEntity id="14987" type="Company"><TargetEntity id="4295880912" type="organizationId">Boryung Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="15872" type="Company"><TargetEntity id="4295876894" type="organizationId">Eisai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16587" type="Company"><TargetEntity id="4296790654" type="organizationId">Gruenenthal GmbH</TargetEntity></SourceEntity><SourceEntity id="16832" type="Company"><TargetEntity id="4296059522" type="organizationId">Takeda AS</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="18105" type="Company"><TargetEntity id="5035561788" type="organizationId">E Merck India Ltd</TargetEntity></SourceEntity><SourceEntity id="19234" type="Company"><TargetEntity id="4297429768" type="organizationId">Rhone-Poulenc Biochimie SA</TargetEntity></SourceEntity><SourceEntity id="19337" type="Company"><TargetEntity id="5035523453" type="organizationId">Rhone Poulenc Rorer Pharm Inc</TargetEntity></SourceEntity><SourceEntity id="20073" type="Company"><TargetEntity id="4298312639" type="organizationId">Pharmacare Ltd</TargetEntity></SourceEntity><SourceEntity id="21266" type="Company"><TargetEntity id="4295873226" type="organizationId">Ranbaxy Laboratories Ltd</TargetEntity></SourceEntity><SourceEntity id="27254" type="Company"><TargetEntity id="4295867409" type="organizationId">Rhone Poulenc SA</TargetEntity></SourceEntity><SourceEntity id="DOL1000087" type="Company"><TargetEntity id="4295892315" type="organizationId">Orient Europharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1101" type="ciIndication"><TargetEntity id="10012434" type="MEDDRA"></TargetEntity><TargetEntity id="445" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3201" type="ciIndication"><TargetEntity id="D012221" type="MeSH"></TargetEntity><TargetEntity id="-1764444025" type="omicsDisease"></TargetEntity><TargetEntity id="299" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3202" type="ciIndication"><TargetEntity id="D006255" type="MeSH"></TargetEntity><TargetEntity id="1184" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="340" type="ciIndication"><TargetEntity id="L50" type="ICD10"></TargetEntity><TargetEntity id="10046735" type="MEDDRA"></TargetEntity><TargetEntity id="D014581" type="MeSH"></TargetEntity><TargetEntity id="-97820952" type="omicsDisease"></TargetEntity><TargetEntity id="448" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="199" type="Action"><TargetEntity id="196" type="Mechanism">Histamine H1 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00915" type="ciTarget"><TargetEntity id="19255861332693" type="siTarget">Histamine H1 receptor</TargetEntity><TargetEntity id="-722811295" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Perennial allergic rhinitis - Spain - Dec-1990</FirstLaunched><FirstLaunched>Seasonal allergic rhinitis - Spain - Dec-1990</FirstLaunched><FirstLaunched>Skin allergy - Spain - Dec-1990</FirstLaunched><FirstLaunched>Urticaria - Spain - Dec-1990</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1101">Skin allergy</Indication><Indication id="3201">Perennial allergic rhinitis</Indication><Indication id="3202">Seasonal allergic rhinitis</Indication><Indication id="340">Urticaria</Indication></IndicationsPrimary><ActionsPrimary><Action id="199">Histamine H1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="15180">Topical antipruritic product</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="746">Solution</Technology><Technology id="750">Freeze drying</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-03T13:12:34.000Z</LastModificationDate><ChangeDateLast>2019-06-04T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by  &lt;ulink linkID="14061" linkType="Company"&gt;Almirall&lt;/ulink&gt; and marketed by various licensees,   ebastine (Bastel; Ebastel; Ebastel Forte; Ebastel Flas; Ebastel Forte Flas; Kestine; Kestin; Kestinlyo; xarope) is an oral non-sedating histamine H1 antagonist indicated in markets outside the US for the symptomatic treatment of seasonal and perennial allergic rhinitis (either associated or not associated with allergic conjunctivitis), chronic idiopathic urticaria and allergic dermatitis  [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;], [&lt;ulink linkID="1349252" linkType="Reference"&gt;1349252&lt;/ulink&gt;], [&lt;ulink linkID="2158096" linkType="Reference"&gt;2158096&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1990, first launch of the drug occurred in Spain [&lt;ulink linkID="1192227" linkType="Reference"&gt;1192227&lt;/ulink&gt;]. In 1996,  licensee &lt;ulink linkID="15606" linkType="Company"&gt;Dainippon&lt;/ulink&gt; (later &lt;ulink linkID="1017117" linkType="Company"&gt;Sumitomo Dainippon&lt;/ulink&gt;) launched the drug in Japan [&lt;ulink linkID="1186356" linkType="Reference"&gt;1186356&lt;/ulink&gt;]. By 2002, the drug had been launched in several  European markets [&lt;ulink linkID="244080" linkType="reference"&gt;244080&lt;/ulink&gt;], [&lt;ulink linkID="452189" linkType="reference"&gt;452189&lt;/ulink&gt;].  In May 1998,  &lt;ulink linkID="19354" linkType="Company"&gt;Rhone-Poulenc Rorer&lt;/ulink&gt; (RPR; now &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;) filed for US approval for symptoms associated with seasonal and perennial allergic rhinitis [&lt;ulink linkID="287257" linkType="reference"&gt;287257&lt;/ulink&gt;]; however, in April 1999, RPR received notice from the FDA indicating that ebastine was not approvable for allergic rhinitis [&lt;ulink linkID="320748" linkType="reference"&gt;320748&lt;/ulink&gt;]. Almirall was to meet with the FDA's Pulmonary-Allergy Drugs advisory committee in December 2002, to discuss US approval [&lt;ulink linkID="470098" linkType="reference"&gt;470098&lt;/ulink&gt;]; however, the meeting was subsequently cancelled and no further development has been reported in the US [&lt;ulink linkID="473742" linkType="reference"&gt;473742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2005, an orally disintegrating tablet formulation (Ebastel Flas) was launched by Almirall [&lt;ulink linkID="1382916" linkType="Reference"&gt;1382916&lt;/ulink&gt;]. By  May 2010, the product was also available in solution and freeze-dried oral formulations [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Granted SPCs on &lt;ulink linkID="IN1157468" linkType="Patent"&gt;EP-00134124&lt;/ulink&gt; expired in the UK and Germany in December 2004, and in other countries in Europe in April 2009. &lt;ulink linkID="IN2259926" linkType="Patent"&gt;EP-00614362&lt;/ulink&gt; covers the composition and expired in December 2012. Generics, including a version from &lt;ulink linkID="1036658" linkType="Company"&gt;KERN Pharma&lt;/ulink&gt;, were available by January 2014 [&lt;ulink linkID="1524700" linkType="Reference"&gt;1524700&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;RPR filed for approval of ebastine for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in May 1998 [&lt;ulink linkID="287257" linkType="reference"&gt;287257&lt;/ulink&gt;]. In April 1999, RPR received an action letter from the FDA indicating that ebastine was not approvable for the treatment of allergic rhinitis. RPR intended to file an amendment to the NDA and expected to meet with the FDA to discuss the filing [&lt;ulink linkID="320748" linkType="reference"&gt;320748&lt;/ulink&gt;]. Almirall was to meet with the FDA's Pulmonary-Allergy Drugs advisory committee on December 20, 2002, to discuss US approval [&lt;ulink linkID="470098" linkType="reference"&gt;470098&lt;/ulink&gt;]. This meeting was subsequently cancelled and no further development has been reported in the US [&lt;ulink linkID="473742" linkType="reference"&gt;473742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;In 1990, the drug was launched in Spain [&lt;ulink linkID="1192227" linkType="Reference"&gt;1192227&lt;/ulink&gt;]. Ebastine was launched in Denmark, Norway, Sweden, Finland and Iceland in 1995 [&lt;ulink linkID="244080" linkType="Reference"&gt;244080&lt;/ulink&gt;]. In April 1997, ebastine was launched in the Netherlands [&lt;ulink linkID="242800" linkType="Reference"&gt;242800&lt;/ulink&gt;]. By May 1998, RPR had launched the drug in Slovakia, Bulgaria, Romania and Malta [&lt;ulink linkID="287257" linkType="Reference"&gt;287257&lt;/ulink&gt;].  In March 2002, the drug was launched by Almirall's German licensee &lt;ulink linkID="1003983" linkType="Company"&gt;Bayer Vital&lt;/ulink&gt; for  seasonal and perennial allergic rhinitis [&lt;ulink linkID="1337266" linkType="Reference"&gt;1337266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2002, &lt;ulink linkID="1002503" linkType="Company"&gt;Takeda Pharmaceuticals International&lt;/ulink&gt; (previously Nycomed; a wholly owned subsidiary of &lt;ulink linkID="20300" linkType="Company"&gt;Takeda Pharmaceutical&lt;/ulink&gt;) had switched the product to OTC status in Sweden and Finland [&lt;ulink linkID="1194003" linkType="Reference"&gt;1194003&lt;/ulink&gt;], [&lt;ulink linkID="1322441" linkType="Reference"&gt;1322441&lt;/ulink&gt;]. By December 2003, Takeda had launched the product in the Baltic countries and Russia; by that time, Takeda had also converted the product to OTC status in Russia [&lt;ulink linkID="1194003" linkType="Reference"&gt;1194003&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;By May 2010, Almirall was marketing ebastine in Germany, Belgium, France and Italy   [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Orally-disintegrating tablet formulation&lt;/subtitle&gt;By May 2010, the orally-disintegrating tablet formulation had been launched in Spain, Finland, Belgium, France and Italy   [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;Dainippon filed for marketing approval in Japan in 1994 for allergy and pruritus indications, for which approval was recommended [&lt;ulink linkID="212110" linkType="Reference"&gt;212110&lt;/ulink&gt;]. The drug had been approved and launched in Japan by December 1996 [&lt;ulink linkID="1186356" linkType="Reference"&gt;1186356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Orally-disintegrating tablet formulation&lt;/subtitle&gt;By May 2010, the orally-disintegrating tablet formulation had been launched in Japan [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Orally-disintegrating tablet formulation&lt;/subtitle&gt;By December 2001, the product had been launched in China [&lt;ulink linkID="452837" linkType="Reference"&gt;452837&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;By May 1998, ebastine had been launched in Colombia, Uruguay, Argentina Venezuela and Mexico [&lt;ulink linkID="287257" linkType="Reference"&gt;287257&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Orally-disintegrating tablet formulation&lt;/subtitle&gt;By May 2010, the orally-disintegrating tablet formulation had been launched in Mexico [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;&lt;subtitle&gt;Orally-disintegrating tablet formulation&lt;/subtitle&gt;By May 2010, the orally-disintegrating tablet formulation had been launched in Turkey [&lt;ulink linkID="1194012" linkType="Reference"&gt;1194012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;By May 1998, ebastine had been launched in Russia and Ukraine [&lt;ulink linkID="287257" linkType="Reference"&gt;287257&lt;/ulink&gt;]. By December 2003, Takeda had also converted the product to OTC status in Russia [&lt;ulink linkID="1194003" linkType="Reference"&gt;1194003&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;By April 1997, E Merck had launched ebastine in Pakistan [&lt;ulink linkID="242800" linkType="Reference"&gt;242800&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;By May 1998, ebastine had been launched in Singapore [&lt;ulink linkID="287257" linkType="Reference"&gt;287257&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In June 2004, clinical data were presented at the 23rd European Academy of Allergology and Clinical Immunology meeting in Amsterdam, the Netherlands. The open-label, parallel-group phase I study enrolled 24 patients with varying degrees of renal insufficiency and 12 healthy volunteers. Pharmacokinetics of ebastine were not modified in patients with renal impairment and there was no correlation between the Cmax of ebastine, its metabolite &lt;ulink linkID="6188" linkType="Drug"&gt;carebastine&lt;/ulink&gt; and creatinine clearance observed. Elimination of the metabolite was also not significantly affected by renal impairment [&lt;ulink linkID="546936" linkType="reference"&gt;546936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in June 2004, further data from a pooled analysis of four randomized, double-blind, placebo-controlled studies of ebastine in patients with seasonal allergic rhinitis were presented at the European Academy of Allergology and Clinical Immunology meeting in Amsterdam, the Netherlands. There was a significant improvement in total efficacy score in the groups rated before the morning dose and the groups rated before bedtime. The improvement began quickly and was sustained through the 4-week period in all studies. In the placebo groups, moderate and severe patients demonstrated a decline in efficacy score by an average of 1.85 and 3.28, respectively. In comparison, those taking ebastine with moderate symptoms had a decline in efficacy scores of 3.17 and 4.74 for moderate and severe patients, respectively. In the placebo groups, moderate patients demonstrated a decline in their nasal congestion scores of an average of 0.4 and for severe patients this was 0.53. Those taking ebastine with moderate symptoms demonstrated a drop in their efficacy scores by 0.58 and those with severe symptoms by 0.81 [&lt;ulink linkID="546936" linkType="reference"&gt;546936&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a study of 12 subjects presented at the CPT meeting (Florence, Italy, July 2000), ebastine (10 mg) had no effect on cognitive performance, sleepiness or alertness [&lt;ulink linkID="376822" linkType="reference"&gt;376822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results presented in March 2000 demonstrated that ebastine 20 mg once daily is equally efficacious in the treatment of seasonal allergic rhinitis when taken with or without food. Also reported at the same meeting was the time to onset of action of ebastine: 60 min for a 20 mg dose and 90 min for a 10 mg dose [&lt;ulink linkID="357015" linkType="reference"&gt;357015&lt;/ulink&gt;], [&lt;ulink linkID="357030" linkType="reference"&gt;357030&lt;/ulink&gt;]. Similar data were presented at the 23rd European Academy of Allergology and Clinical Immunology meeting in Amsterdam, the Netherlands [&lt;ulink linkID="546936" linkType="reference"&gt;546936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An open label study investigating the pharmacokinetics of ebastine was presented in March 2000. Participating were 24 patients with varying stages of liver cirrhosis and 12 healthy volunteers. The patients received either a single 10 mg dose of ebastine or 10 mg/20 mg ebastine daily over 7 days. Plasma samples were analyzed for ebastine and the active metabolite, carabastine, on days 1 and 7. No statistical differences in Tmax, Cmax or AUC for ebastine or carabastine were observed between patients with liver cirrhosis and healthy volunteers [&lt;ulink linkID="363326" linkType="reference"&gt;363326&lt;/ulink&gt;] . &lt;/para&gt;&lt;para&gt;The effects of &lt;ulink linkID="2752" linkType="Drug"&gt;cetirizine&lt;/ulink&gt; (10 mg), ebastine (10 mg), &lt;ulink linkID="3049" linkType="Drug"&gt;epinastine&lt;/ulink&gt; (20 mg; qv), &lt;ulink linkID="8860" linkType="Drug"&gt;fexofenadine&lt;/ulink&gt; (60 mg), terfenadine (60 mg) and &lt;ulink linkID="3516" linkType="Drug"&gt;loratadine&lt;/ulink&gt; (10 mg) on epicutaneous histamine phosphate (100 mg/ml) were evaluated in 14 healthy males. Inhibition of wheal area of &amp;gt; 95% was shown by 13/14 subjects when treated with &lt;ulink linkID="2752" linkType="Drug"&gt;cetirizine&lt;/ulink&gt;, 6/14 when treated with terfenadine, &lt;ulink linkID="3049" linkType="Drug"&gt;epinastine&lt;/ulink&gt; or ebastine, 5/14 when treated with &lt;ulink linkID="8860" linkType="Drug"&gt;fexofenadine&lt;/ulink&gt; and 2/14 when treated with &lt;ulink linkID="3516" linkType="Drug"&gt;loratadine&lt;/ulink&gt; [&lt;ulink linkID="315592" linkType="reference"&gt;315592&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Studies have demonstrated that 20 mg ebastine is superior to 10 mg &lt;ulink linkID="3516" linkType="Drug"&gt;loratadine&lt;/ulink&gt;, producing an improvement in total symptom scores and a lower rate of discontinuation due to ineffective treatment. The drug was well tolerated and had a similar safety profile to that of placebo [&lt;ulink linkID="315728" linkType="reference"&gt;315728&lt;/ulink&gt;], [&lt;ulink linkID="315729" linkType="reference"&gt;315729&lt;/ulink&gt;], [&lt;ulink linkID="317564" linkType="reference"&gt;317564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a guinea pig model, ebastine was found to have no significant effects on the QTc interval, even at a dose 120 times higher than an equivalent dose of terfenadine [&lt;ulink linkID="315727" linkType="reference"&gt;315727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; Ebastine given prophylactically has been shown to reduce pruritus associated with mosquito bites in mosquito-allergic individuals [&lt;ulink linkID="356343" linkType="reference"&gt;356343&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-29T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-01T00:00:00.000Z</StatusDate><Source id="1382916" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042568">Laboratorios Servimedic</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042567">Highnoon Laboratories Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="1186356" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="VN">Vietnam</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042568">Laboratorios Servimedic</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20073">Pharmacare Ltd</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042566">Eurofarma</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003983">Bayer HealthCare AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-31T00:00:00.000Z</StatusDate><Source id="1337266" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042566">Eurofarma</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019881">Laboratorios Elmor SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MT">Malta</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1036448">Novis Pharmaceuticals Llc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003983">Bayer HealthCare AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-31T00:00:00.000Z</StatusDate><Source id="1337266" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042568">Laboratorios Servimedic</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-29T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1036448">Novis Pharmaceuticals Llc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="VN">Vietnam</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MT">Malta</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1993-10-18T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="1186356" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-29T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1993-10-18T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019881">Laboratorios Elmor SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="1186356" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1036448">Novis Pharmaceuticals Llc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-01T00:00:00.000Z</StatusDate><Source id="1382916" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-26T00:00:00.000Z</StatusDate><Source id="1349252" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-01T00:00:00.000Z</StatusDate><Source id="1382916" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20073">Pharmacare Ltd</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="1186356" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-26T00:00:00.000Z</StatusDate><Source id="1349252" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-26T00:00:00.000Z</StatusDate><Source id="1349252" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1990-12-31T00:00:00.000Z</StatusDate><Source id="1192227" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042568">Laboratorios Servimedic</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20073">Pharmacare Ltd</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042567">Highnoon Laboratories Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042566">Eurofarma</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="VN">Vietnam</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1993-10-18T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1036448">Novis Pharmaceuticals Llc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MT">Malta</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003983">Bayer HealthCare AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-31T00:00:00.000Z</StatusDate><Source id="1337266" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042567">Highnoon Laboratories Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20073">Pharmacare Ltd</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1990-12-31T00:00:00.000Z</StatusDate><Source id="1192227" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1990-12-31T00:00:00.000Z</StatusDate><Source id="1192227" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-26T00:00:00.000Z</StatusDate><Source id="1349252" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019881">Laboratorios Elmor SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042566">Eurofarma</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042567">Highnoon Laboratories Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-29T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="VN">Vietnam</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="MT">Malta</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14987">Boryung Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1993-10-18T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1227034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1990-12-31T00:00:00.000Z</StatusDate><Source id="1192227" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003983">Bayer HealthCare AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-31T00:00:00.000Z</StatusDate><Source id="1337266" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-01T00:00:00.000Z</StatusDate><Source id="1382916" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019881">Laboratorios Elmor SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1226846" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27254">Aventis SA</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-08T00:00:00.000Z</StatusDate><Source id="443244" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-03-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-04-14T00:00:00.000Z</StatusDate><Source id="1455142" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-11-14T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1993-09-21T00:00:00.000Z</StatusDate><Source id="165930" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-31T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18105">E Merck India Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-12-11T00:00:00.000Z</StatusDate><Source id="1460375" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-12-11T00:00:00.000Z</StatusDate><Source id="1460375" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><Source id="1454583" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-08-21T00:00:00.000Z</StatusDate><Source id="216367" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-31T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-04-14T00:00:00.000Z</StatusDate><Source id="1455142" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><Source id="1454583" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-12-11T00:00:00.000Z</StatusDate><Source id="1460375" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-12-11T00:00:00.000Z</StatusDate><Source id="1460375" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-08-21T00:00:00.000Z</StatusDate><Source id="216367" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-08-21T00:00:00.000Z</StatusDate><Source id="216367" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-08-21T00:00:00.000Z</StatusDate><Source id="216367" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-04-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-04-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-04-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-03-01T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-03-01T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-03-01T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18105">E Merck India Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18105">E Merck India Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18105">E Merck India Ltd</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate><Source id="242800" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="PK">Pakistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1045551" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-05-20T00:00:00.000Z</StatusDate><Source id="452189" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-05-20T00:00:00.000Z</StatusDate><Source id="452189" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-05-20T00:00:00.000Z</StatusDate><Source id="452189" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14061">Almirall Prodesfarma SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-05-20T00:00:00.000Z</StatusDate><Source id="452189" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="UY">Uruguay</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-11-14T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-11-14T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-11-14T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16832">Nycomed AS</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="452837" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-14T00:00:00.000Z</StatusDate><Source id="287257" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19337">Rhone-Poulenc Rorer Pharm Inc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="244080" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-03-01T00:00:00.000Z</StatusDate><Source id="165714" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1101">Skin allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-04-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00915"><Name>Histamine H1 receptor</Name><SwissprotNumbers><Swissprot>P30546</Swissprot><Swissprot>P31389</Swissprot><Swissprot>P31390</Swissprot><Swissprot>P35367</Swissprot><Swissprot>P70174</Swissprot><Swissprot>Q9N2B0</Swissprot><Swissprot>Q9N2B1</Swissprot><Swissprot>Q9N2B2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2152653" linkType="reference" linkID="2152653"&gt;2152653&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1019374">Aspen PharmaCare Holdings Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1019881">Laboratorios Elmor SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1036448">Novis Pharmaceuticals Llc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1042566">Eurofarma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1042567">Highnoon Laboratories Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1042568">Laboratorios Servimedic</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1046809">Meiji Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14061">Almirall Prodesfarma SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>19</CountTotal></Company><Company><Company id="14987">Boryung Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16587">Grunenthal GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27561">Sun Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30256">Eczacibasi Ozgun Kimyasal Urunler Sanayi ve Ticaret AS</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000087">Orient Europharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>15</CountActive><CountInactive>1</CountInactive><CountTotal>16</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)(C)c1ccc(cc1)C(=O)CCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4</Smiles></StructureSmiles><Deals><Deal id="114250" title="Rhone-Poulenc Rorer to develop Almirall's ebastine in the US"></Deal><Deal id="116381" title="Dainippon to conduct clinical trials of Almirall's ebastine"></Deal><Deal id="116383" title="Meiji Seika Kaisha to comarket Almirall's ebastine in Japan with Dainippon"></Deal><Deal id="116385" title="Boryung to market Almirall's ebastine in South Korea"></Deal><Deal id="116386" title="Eisai to market Almirall's ebastine in China"></Deal><Deal id="116387" title="Elmor to market Almirall's ebastine and aceclofenac in Venezuela"></Deal><Deal id="116391" title="Eurofarma to market Almirall's ebastine and aceclofenac in Brazil"></Deal><Deal id="116394" title="Highnoon to market Almirall's ebastine and aceclofenac in Pakistan"></Deal><Deal id="116396" title="Nycomed to market Almirall's ebastine in various regions    "></Deal><Deal id="116399" title="Pharmacare to market Almirall's ebastine in South Africa"></Deal><Deal id="116400" title="Merck KGaA to market Almirall's ebastine in Germany, Switzerland, and Austria"></Deal><Deal id="116403" title="Servimedic to market Almirall's ebastine in Uruguay"></Deal><Deal id="121836" title="Bristol-Myers Squibb to license Almirall Prodesfarma's aceclofenac in Latin America and aceclofenac and ebastine in Egypt"></Deal><Deal id="128162" title="Novis to market Almirall's aceclofenac and ebastine in Greece"></Deal><Deal id="128201" title="Chiesi to market Almirall's ebastine in Italy"></Deal><Deal id="128203" title="Eczacibasi to market Almirall's ebastine in Turkey"></Deal><Deal id="128211" title="Grunenthal to market Almirall's ebastine in Ecuador"></Deal><Deal id="128213" title="Orient Europharma to market Almirall's ebastine in Taiwan"></Deal><Deal id="128214" title="Ranbaxy to market Almirall's ebastine in Singapore and Vietnam"></Deal></Deals><PatentFamilies><PatentFamily id="1046480" number="IN-200600738" title="Preparation of ebastine having specific particle size range"></PatentFamily><PatentFamily id="1105935" number="WO-2007051877" title="Solid oral forms of ebastine"></PatentFamily><PatentFamily id="1243655" number="JP-2008143853" title="The orally disintegrating tablet which uses ebastine as active drug substance"></PatentFamily><PatentFamily id="1345228" number="EP-00134124" title="Piperidine derivatives"></PatentFamily><PatentFamily id="140220" number="KR-00574088" title="Ebastine drug preparation with improvded elution rate comprising slightly soluble ebastine as an anti-histamine drug and process for manufacturing the same"></PatentFamily><PatentFamily id="1474460" number="CN-101161233" title="Ebastine solid oral preparation and preparing method"></PatentFamily><PatentFamily id="1524054" number="JP-05036126" title="Ebastine orally administrating formulation"></PatentFamily><PatentFamily id="1541606" number="EP-01716848" title="Solid pharmaceutical composition containing a crystalline derivative of piperidine substituted in the 1,4 position"></PatentFamily><PatentFamily id="1546032" number="WO-03076399" title="Compounds capable of inhibiting immunocyte-related allergic immune reactions"></PatentFamily><PatentFamily id="1600135" number="JP-2007297348" title="The tablet containing ebastine"></PatentFamily><PatentFamily id="1604195" number="JP-2010111667" title="Pharmaceutical composition for the anti-tussive containing a fexofenadine or ebastine, and/or an expectorant"></PatentFamily><PatentFamily id="1687685" number="CN-102095808" title="Analysis method of related substances in ebastine"></PatentFamily><PatentFamily id="1810521" number="WO-2007017028" title="Tablets with improved dissolution profile"></PatentFamily><PatentFamily id="1853413" number="DE-202011000756" title="Ebastine obtained by a method comprising reacting 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-hydroxypiperidine-1-yl)butan-1-one and diphenylmethanol in presence of a dehydrating agent in an organic solvent system, useful to prepare a composition"></PatentFamily><PatentFamily id="1853674" number="WO-2011121099" title="Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof"></PatentFamily><PatentFamily id="2050724" number="WO-2006135689" title="Nanoparticulate ebastine formulations"></PatentFamily><PatentFamily id="2114427" number="ES-02231043" title="Instant release pharmaceutical consists of a cellulose disaggregating excipient coated with non micronized solution"></PatentFamily><PatentFamily id="2127316" number="WO-09310782" title="Pharmaceutical compositions based on ebastine or analogues thereof."></PatentFamily><PatentFamily id="2259246" number="JP-2002338486" title="The object for cold|flus, and the composition for rhinitis"></PatentFamily><PatentFamily id="2266803" number="JP-2008120685" title="An ebastine orally administrating formulation and its manufacturing method"></PatentFamily><PatentFamily id="2342828" number="WO-2009157006" title="Process of preparing ebastine"></PatentFamily><PatentFamily id="2465712" number="WO-2013017821" title="Pharmaceutical composition comprising ebastine and fluticasone"></PatentFamily><PatentFamily id="2519040" number="WO-2013062498" title="Solid oral formulations comprising ebastine"></PatentFamily><PatentFamily id="2524879" number="WO-2013065068" title="Oral disintegrating composition of anti-histamine agents"></PatentFamily><PatentFamily id="2547473" number="CN-103127012" title="A kind of ebastine dispersible tablet and preparation method thereof"></PatentFamily><PatentFamily id="255136" number="WO-2006080415" title="Composition and method for treating or preventing bladder disorder"></PatentFamily><PatentFamily id="286578" number="CN-01868474" title="Ebastine tablet and its prepn. method"></PatentFamily><PatentFamily id="3137988" number="CN-105326802" title="Ebastine dispersible tablet and preparation method thereof"></PatentFamily><PatentFamily id="3243046" number="CN-105687128" title="An ebastine oral liquid and preparation method thereof"></PatentFamily><PatentFamily id="3253688" number="WO-2016116438" title="Antihistamine for use in treatment of breast cancer"></PatentFamily><PatentFamily id="3377003" number="EP-02589376" title="Oral disintegrating composition of anti-histamine agents"></PatentFamily><PatentFamily id="3503789" number="CN-106237004" title="A western preparation and preparation method for treating chronic simple moss"></PatentFamily><PatentFamily id="3690784" number="WO-2017102640" title="Use of histamine metabolites as markers for the treatment of IBS with H1-R antagonists"></PatentFamily><PatentFamily id="4056627" number="CN-107982274" title="Pharmaceutical composition for treating urticaria and preparation method thereof"></PatentFamily><PatentFamily id="419537" number="JP-2010083871" title="Pharmaceutical composition containing an anti- adenovirus agent"></PatentFamily><PatentFamily id="424719" number="CN-100443470" title="Preparation of ebastine"></PatentFamily><PatentFamily id="4477379" number="CN-109593058" title="Preparation method of ebastine"></PatentFamily><PatentFamily id="4538164" number="US-20190169620" title="Treatment of HER2-dependent cancers by SORL1 inhibition"></PatentFamily><PatentFamily id="523320" number="CN-102218041" title="Ebastine solid dispersion and high-dissolubility ebastine tablet prepared by the same"></PatentFamily><PatentFamily id="581745" number="EP-01719501" title="A powder composition comprising a mixture of a hydrophilic polymer matrix and a divalent inorganic metal"></PatentFamily><PatentFamily id="819375" number="KR-2011126443" title="The pharmaceutical mixture including the leukotriene antagonist and antihistamine system drug"></PatentFamily><PatentFamily id="861432" number="DE-102008000351" title="Verfahren zur herstellung eines ebastin enthaltenden granulats sowie einer festen pharmazeutischen zusammensetzung, ebastin enthaltendes granulat und dessen verwendung"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>27</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Y's Therapeutics Co Ltd" id="1007028"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Meditech Korea Pharm Co Ltd" id="1015817"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daiichi Sankyo Co Ltd" id="1017506"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Simbec Iberica SL" id="1017935"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Lianhuan Pharmaceutical Co Ltd" id="1027708"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Micro Labs Ltd" id="1028350"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tonira Pharma Ltd" id="1029485"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Meiji Holdings Co Ltd" id="1046809"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Navipharm Co Ltd" id="1056771"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Huabangshengkai Pharm Co Ltd" id="1060259"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Inopharm Ltd" id="1062613"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arevipharma GmbH" id="1065319"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Partners För Utvecklingsinvesteringar Inom Life Sciences Puls AB" id="1067719"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Aoyipollen Pharmaceutical Co Ltd" id="1068303"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jawaharlal Nehru Technological University" id="1070810"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Meheco Co Ltd" id="1080978"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Zijin Pharmaceutical Technology Co Ltd" id="1099363"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Belina Pharma AB" id="1151259"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hunan Bojun Biological Medicine Co Ltd" id="1170862"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akzo Nobel NV" id="13802"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Almirall Prodesfarma SA" id="14061"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alter SA" id="14092"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nichi-Iko Pharmaceutical Co Ltd" id="18511"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taisho Pharmaceutical Co Ltd" id="20289"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tokyo" id="20686"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yoshindo Inc" id="20982"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daito KK" id="21677"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fordonal SA" id="22500"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Katholieke Universiteit Leuven" id="23009"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitaet Gent" id="24987"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Lund" id="25208"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lindopharm GmbH" id="25799"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Cinfa SA" id="29507"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Turku" id="DOL1000739"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>